

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 25, 2022**



**Acutus Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)**

**Delaware
(State or Other Jurisdiction
of Incorporation)**

**001-39430
(Commission File Number)**

**45-1306615
(IRS Employer
Identification No.)**

**2210 Faraday Ave., Suite 100
Carlsbad, CA
(Address of Principal Executive Offices)**

**92008
(Zip Code)**

Registrant's Telephone Number, Including Area Code: (442) 232-6080

**Not Applicable
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value \$0.001	AFIB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective July 25, 2022, and in accordance with the terms of the Acutus Medical, Inc. 2011 Equity Incentive Plan and the Acutus Medical, Inc. 2020 Equity Incentive Plan (the “Incentive Plans”), the Board of Directors (the “Board”) of Acutus Medical, Inc. (the “Company”) reduced the exercise price of outstanding options to purchase the Company’s common stock held by employees of the Company who were employed on July 25, 2022 (and who had not provided a notice of resignation prior to such date) (the “Designated Options”) to \$1.34 per share, which was the closing price for the Company’s common stock on July 25, 2022. The exercise price reduction includes options held by, among others, the Company’s Chief Executive Officer, David Roman, with respect to 127,335 shares (with original exercise prices ranging from \$2.41 to \$13.66).

Except for the reduction in the exercise price of the Designated Options, all outstanding stock options continue to remain outstanding in accordance with their current terms and conditions as set forth in the Incentive Plans and award agreements thereunder.

Item 9.01. **Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Acutus Medical, Inc.

Date: July 29, 2022

By: /s/ Tom Sohn
Tom Sohn
SVP, General Counsel